Novartis
NVS
NVS
1,181 hedge funds and large institutions have $15.2B invested in Novartis in 2023 Q1 according to their latest regulatory filings, with 97 funds opening new positions, 353 increasing their positions, 499 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
0% less funds holding
Funds holding: 1,183 → 1,181 (-2)
1% less capital invested
Capital invested by funds: $15.3B → $15.2B (-$109M)
29% less repeat investments, than reductions
Existing positions increased: 353 | Existing positions reduced: 499
Holders
1,181
Holding in Top 10
14
Calls
$564M
Puts
$226M
Top Buyers
1 | +$255M | |
2 | +$114M | |
3 | +$102M | |
4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$94.3M |
5 |
Millennium Management
New York
|
+$85.9M |
Top Sellers
1 | -$399M | |
2 | -$363M | |
3 | -$98.8M | |
4 |
Primecap Management
Pasadena,
California
|
-$70.6M |
5 |
MSE
MUFG Securities EMEA
London,
United Kingdom
|
-$55.1M |